|
Back to Home » January 2019 News » NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea |
NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea |
January 03, 2019
AMSTERDAM and SEOUL, South Korea, January 3, 2019 /PRNewswire/ -- Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE...
Source URL: https://www.prnewswire.com:443/news-releases/norgine-b-v-and-korea-pharma-co-ltd-enter-into-exclusive-licence-agreement-for-the-commercialisation-of-plenvu-r-in-the-republic-of-korea-888171036.html
|
|
|
|
